Original Article J Gynecol Oncol Vol. 26, No. 2:90-99 http://dx.doi.org/10.3802/jgo.2015.26.2.90 pISSN 2005-0380 · eISSN 2005-0399
Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial Ju-Won Roh1,*, Dong Ock Lee2, Dong Hoon Suh3, Myong Cheol Lim2, Sang-Soo Seo2, Jinsoo Chung4, Sun Lee5, Sang-Yoon Park2,*
1
Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang; Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang; 3Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; 4Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang; 5Department of Pathology, Kyung Hee University School of Medicine, Seoul, Korea 2
See accompanying editorial by Sakuragi on page 81.
Objective: A prospective, randomized controlled trial was conducted to evaluate the efficacy of nerve-sparing radical hysterectomy (NSRH) in preserving bladder function and its oncologic safety in the treatment of cervical cancer. Methods: From March 2003 to November 2005, 92 patients with cervical cancer stage IA2 to IIA were randomly assigned for surgical treatment with conventional radical hysterectomy (CRH) or NSRH, and 86 patients finally included in the analysis. Adequacy of nerve sparing, radicality, bladder function, and oncologic safety were assessed by quantifying the nerve fibers in the paracervix, measuring the extent of paracervix and harvested lymph nodes (LNs), urodynamic study (UDS) with International Prostate Symptom Score (IPSS), and 10-year disease-free survival (DFS), respectively. Results: There were no differences in clinicopathologic characteristics between two groups. The median number of nerve fiber was 12 (range, 6 to 21) and 30 (range, 17 to 45) in the NSRH and CRH, respectively (p
Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial Ju-Won Roh1,*, Dong Ock Lee2, Dong Hoon Suh3, Myong Cheol Lim2, Sang-Soo Seo2, Jinsoo Chung4, Sun Lee5, Sang-Yoon Park2,*
1
Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang; Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang; 3Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; 4Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang; 5Department of Pathology, Kyung Hee University School of Medicine, Seoul, Korea 2
See accompanying editorial by Sakuragi on page 81.
Objective: A prospective, randomized controlled trial was conducted to evaluate the efficacy of nerve-sparing radical hysterectomy (NSRH) in preserving bladder function and its oncologic safety in the treatment of cervical cancer. Methods: From March 2003 to November 2005, 92 patients with cervical cancer stage IA2 to IIA were randomly assigned for surgical treatment with conventional radical hysterectomy (CRH) or NSRH, and 86 patients finally included in the analysis. Adequacy of nerve sparing, radicality, bladder function, and oncologic safety were assessed by quantifying the nerve fibers in the paracervix, measuring the extent of paracervix and harvested lymph nodes (LNs), urodynamic study (UDS) with International Prostate Symptom Score (IPSS), and 10-year disease-free survival (DFS), respectively. Results: There were no differences in clinicopathologic characteristics between two groups. The median number of nerve fiber was 12 (range, 6 to 21) and 30 (range, 17 to 45) in the NSRH and CRH, respectively (p
